Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maysiglu (sitagliptin) is used within the antidiabetic therapeutic pathway to improve glycaemic control in patients with type 2 diabetes.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose as monotherapy or in combination with other agents. - Adjunct to diet and exercise: helps patients achieve target HbA1c levels when lifestyle measures are inadequate. - Combination therapy with metformin: provides additional glucose reduction for patients requiring dual oral therapy.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory tract infection: cough, sore throat. - Gastrointestinal upset: nausea, abdominal discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe joint pain: arthralgia with swelling.

When prescribing sitagliptin, clinicians should consider patient‑specific factors and safety measures.

- Renal impairment: assess kidney function and adjust dose if needed. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: monitor closely for recurrent episodes. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; adjust co‑therapy accordingly. - Allergic reactions: discontinue if severe rash or anaphylaxis occurs. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can increase exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: additive glucose‑lowering effect may cause hypoglycaemia. - Rifampin: enzyme induction may reduce sitagliptin effectiveness. - Diuretics: may affect glucose control and require monitoring.